THORNTON, CO – MARCH 06: Adams 12 Five Star Schools District RN Tiffany Karschamroon draws a dose from a vial of the Johnson & Johnson COVID-19 vaccine, the newest vaccine approved by the U.S. FDA for emergency use, at an event put on by the Thornton Fire Department on March 6, 2021 in Thornton, Colorado. Colorado entered COVID-19 vaccination Phase 1B.3 on Friday, allowing essential grocery and agriculture workers, people over the age of 60 and people with two or more high-risk conditions to receive a vaccine. (Photo by Michael Ciaglo/Getty Images).
WASHINGTON (AP) — The U.S. is recommending a “pause” in using the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots. The Centers for Disease Control and Prevention and the Food and Drug Administration said Tuesday they were investigating clots in six women in the days after vaccination, in combination with reduced platelet counts. More than 6.8 million doses of the J&J vaccine have been given in the U.S., the vast majority with no or mild side effects. A CDC committee will meet Wednesday to discuss the cases and the FDA has also launched an investigation.
As of 4/12, 6.8m+ doses of the J&J vaccine have been administered in the U.S. CDC & FDA are reviewing data involving 6 reported U.S. cases of a rare & severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare
— U.S. FDA (@US_FDA) April 13, 2021
“CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases.” US Food and Drug Administration continued to tweet, “Until that process is complete, we are recommending this pause. This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot.”
